---
title: "Bliss GVS Pharma Ltd (BLISSGVS) — Share Price, Financials & Analysis"
symbol: "BLISSGVS"
company: "Bliss GVS Pharma Ltd"
canonical: "https://tapetide.com/stocks/BLISSGVS"
isin: "INE416D01022"
nse_symbol: "BLISSGVS"
bse_code: "506197"
sector: "Healthcare"
industry: "Pharmaceuticals"
market_cap_cr: 7362.91
generated_at: "2026-09-13T20:00:07.652Z"
---

# Bliss GVS Pharma Ltd (BLISSGVS)

Canonical page: https://tapetide.com/stocks/BLISSGVS

## Company

- **NSE Symbol:** BLISSGVS
- **BSE Code:** 506197
- **ISIN:** INE416D01022
- **Sector:** Healthcare
- **Industry:** Pharmaceuticals
- **Macro Sector:** Healthcare
- **Stock Type:** EQUITY
- **Listed Since:** 2010-07-30
- **CEO:** Dr. Vibha Gagan Sharma
- **Employees:** 966
- **Face Value:** ₹1
- **F&O Eligible:** No
- **Website:** blissgvs.com

## About

Incorporated in 1984, Bliss GVS Pharma Limited is engaged in manufacturing, marketing, trading and export of pharmaceutical formulations in the form of suppositories, pessaries, capsules, tablets, and syrups.

## Latest Price

- **Price:** ₹720.95
- **Change:** +20.5 (+2.93%)
- **Open:** ₹698
- **Day High:** ₹724
- **Day Low:** ₹676
- **Previous Close:** ₹700.45
- **Volume:** 190726
- **As Of:** 2026-09-11T10:29:23+00:00

## Key Fundamentals

Observed at 2026-09-11T04:38:03.135389Z.

- **Market Cap:** ₹7362.91 Cr
- **Classification:** Microcap
- **P/E (reported):** 52.8
- **P/E (TTM):** 56.06
- **EPS (TTM):** ₹12.86
- **Book Value:** ₹112.19
- **Price to Book:** 6.27
- **Dividend Yield:** 0.21%
- **ROE:** 10.94%
- **ROCE:** 16.04%
- **Debt to Equity:** 0.02
- **Revenue (yearly):** ₹1000.6 Cr
- **Net Income:** ₹134.7 Cr
- **EBITDA:** ₹237.6 Cr
- **52-Week High:** ₹725.9
- **52-Week Low:** ₹118
- **RSI (14):** 74.26

## Tapetide Score

- **Score:** 40 / 100
- **Score date:** 2026-09-04
- **Archetype:** Trend Ahead of Fundamentals
- **What it means:** The price trend is running ahead of what the financials currently support. Moves like this depend on the fundamentals catching up; check what would have to be true for that.
- **Pillar profile:** Quality: Weak · Valuation: Expensive · Momentum: Rising
- **Percentile:** 14.5 (of 4473 scored stocks)
- **Confidence:** 100%
- **Data coverage:** 100%

| Pillar | Score | Weight |
| --- | --- | --- |
| financial health | 83.18 | 9% |
| growth | 61.19 | 9% |
| momentum | 98.9 | 12% |
| ownership | 34.1 | 24% |
| quality | 45.06 | 22% |
| valuation | 47.19 | 24% |

The Tapetide Score is decision-support only, not investment advice.

## Key Insights

### Strengths

- Company has reduced debt.
- Company is almost debt free.

### Weaknesses

- Stock is trading at 6.39 times its book value
- The company has delivered a poor sales growth of 9.94% over past five years.
- Company has a low return on equity of 10.2% over last 3 years.
- Company has high debtors of 204 days.

## Growth Rates

| Metric | QoQ | 1Y | 3Y | 5Y |
| --- | --- | --- | --- | --- |
| cash flow growth | — | 30.98% | 34.92% | 2.39% |
| ebitda margin growth | 54.68% | 23.13% | 5.75% | 23.39% |
| net income growth | 38.92% | 49.17% | 23% | 14% |
| revenue growth | 10.07% | 18.25% | 7% | 10% |
| roce | 61.97% | 35.36% | 36.63% | 11.69% |
| roe | 38.84% | 32.29% | 9.11% | 300.73% |

## Financial Statements

### Quarterly Results

All figures in ₹ crore unless the row name says otherwise.

| Item | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 212 | 201 | 198 | 184 | 218 | 210 | 198 | 207 | 244 | 218 | 257 | 286 |
| Expenses | 158 | 157 | 170 | 149 | 176 | 181 | 177 | 166 | 201 | 183 | 213 | 209 |
| Operating Profit | 54 | 44 | 28 | 34 | 41 | 30 | 21 | 41 | 43 | 35 | 44 | 76 |
| OPM % | 26 | 22 | 14 | 19 | 19 | 14 | 11 | 20 | 18 | 16 | 17 | 27 |
| Other Income | 13 | 5 | -24 | 4 | 5 | 15 | 12 | 35 | 8 | 16 | 11 | 10 |
| Interest | 1 | 2 | 2 | 2 | 4 | 1 | 2 | 5 | 3 | 1 | 2 | 1 |
| Depreciation | 6 | 7 | 7 | 7 | 7 | 8 | 8 | 8 | 8 | 8 | 9 | 10 |
| Profit before tax | 59 | 40 | -4 | 30 | 36 | 36 | 23 | 63 | 41 | 41 | 45 | 75 |
| Tax % | 27 | 27 | 24 | 26 | 28 | 29 | 29 | 30 | 30 | 39 | 18 | 32 |
| Net Profit | 43 | 29 | -5 | 22 | 26 | 26 | 17 | 44 | 29 | 25 | 37 | 51 |
| EPS in Rs | 4.05 | 2.64 | -0.87 | 1.97 | 2.31 | 2.26 | 1.47 | 4.08 | 2.58 | 2.2 | 3.36 | 4.72 |

### Profit & Loss

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 815 | 899 | 689 | 577 | 747 | 752 | 770 | 810 | 927 | 1005 |
| Expenses | 618 | 739 | 566 | 471 | 629 | 634 | 620 | 683 | 760 | 806 |
| Operating Profit | 197 | 160 | 123 | 107 | 118 | 117 | 151 | 127 | 168 | 199 |
| OPM % | 24 | 18 | 18 | 18 | 16 | 16 | 20 | 16 | 18 | 20 |
| Other Income | -8 | 35 | 26 | 20 | -42 | 18 | 0 | 36 | 67 | 45 |
| Interest | 23 | 4 | 8 | 6 | 5 | 10 | 7 | 8 | 12 | 7 |
| Depreciation | 21 | 9 | 13 | 17 | 17 | 19 | 26 | 29 | 33 | 35 |
| Profit before tax | 145 | 182 | 129 | 104 | 54 | 106 | 117 | 126 | 190 | 202 |
| Tax % | 39 | 30 | 26 | 29 | 57 | 28 | 30 | 28 | 29 | — |
| Net Profit | 89 | 127 | 95 | 74 | 23 | 77 | 82 | 90 | 135 | 142 |
| EPS in Rs | 5.7 | 11.99 | 9.43 | 6.64 | 1.45 | 6.8 | 7.21 | 8 | 12.21 | 12.86 |
| Dividend Payout % | 18 | 8 | 5 | 8 | 34 | 7 | 7 | 6 | 4 | — |

### Balance Sheet

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Equity Capital | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 11 | 11 |
| Reserves | 476 | 526 | 636 | 725 | 798 | 808 | 873 | 957 | 1040 | 1182 |
| Borrowings | 225 | 118 | 102 | 126 | 122 | 109 | 102 | 100 | 88 | 22 |
| Other Liabilities | 311 | 206 | 157 | 168 | 147 | 181 | 171 | 145 | 163 | 278 |
| Total Liabilities | 1023 | 860 | 905 | 1030 | 1077 | 1109 | 1157 | 1212 | 1301 | 1492 |
| Fixed Assets | 305 | 143 | 146 | 242 | 234 | 281 | 379 | 370 | 406 | 459 |
| CWIP | 4 | 0 | 47 | 0 | 2 | 22 | 3 | 8 | 21 | 6 |
| Investments | 0 | 0 | 0 | 0 | 0 | 2 | 8 | 4 | 4 | 5 |
| Other Assets | 714 | 717 | 712 | 788 | 840 | 803 | 768 | 830 | 871 | 1022 |
| Total Assets | 1023 | 860 | 905 | 1030 | 1077 | 1109 | 1157 | 1212 | 1301 | 1492 |

### Cash Flow

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash from Operating Activity | 289 | 18 | 40 | 47 | 64 | 135 | 34 | 103 | 106 | 139 |
| Cash from Investing Activity | -249 | 48 | -79 | -40 | -45 | -103 | -6 | -83 | -75 | -38 |
| Cash from Financing Activity | -10 | -76 | 17 | -6 | -21 | -24 | -25 | -21 | -30 | -89 |
| Net Cash Flow | 30 | -10 | -22 | 0 | -2 | 9 | 3 | -1 | 0 | 11 |
| Free Cash Flow | 186 | -7 | 2 | -12 | 55 | 63 | -59 | 75 | 33 | 84 |
| CFO/OP | 160 | 29 | -8 | 69 | 87 | 143 | 67 | 91 | 112 | 108 |

### Ratios

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Debtor Days | 116 | 134 | 187 | 290 | 293 | 192 | 187 | 192 | 198 | 204 |
| Inventory Days | 50 | 55 | 46 | 64 | 110 | 116 | 94 | 113 | 111 | 129 |
| Days Payable | 100 | 55 | 47 | 75 | 82 | 86 | 79 | 58 | 63 | 89 |
| Cash Conversion Cycle | 67 | 134 | 186 | 279 | 321 | 221 | 202 | 247 | 246 | 244 |
| Working Capital Days | -10 | 135 | 154 | 232 | 264 | 179 | 192 | 207 | 198 | 214 |
| ROCE % | 29 | 27 | 26 | 18 | 12 | 14 | 12 | 14 | 12 | 17 |

## Shareholding Pattern

### Quarterly

| Category | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Promoters | 35.06% | 34.97% | 34.97% | 34.9% | 34.82% | 35.1% | 35.29% | 35.44% | 35.39% | 35.36% | 35.36% | 35.01% |
| FIIs | 16.31% | 15.35% | 14.73% | 13.25% | 12.13% | 13.51% | 13.18% | 12.65% | 13.27% | 14.54% | 10.45% | 8.07% |
| DIIs | 6.61% | 6.59% | 6.59% | 6.58% | 6.57% | 6.55% | 6.55% | 6.54% | 5.98% | 5.78% | 5.04% | 9.47% |
| Government | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Public | 29.17% | 30.78% | 31.71% | 32.84% | 34.57% | 32.93% | 32.63% | 32.79% | 32.85% | 31.48% | 32.6% | 29.77% |
| Others | 12.84% | 12.31% | 12% | 12.43% | 11.92% | 11.91% | 12.34% | 12.58% | 12.51% | 12.84% | 16.55% | 17.68% |
| No. of Shareholders | 43234 | 40758 | 45157 | 44737 | 52937 | 49558 | 49517 | 46707 | 44461 | 43380 | 44874 | 46767 |

## Technical Indicators

Derived from daily closing prices and recomputed each trading session; values move with the market.

- **Overall Signal:** Strong Buy
- **Buy / Neutral / Sell:** 13 / 3 / 3

### Moving Averages — summary: **Strong Buy**

| Indicator | Value | Signal |
| --- | --- | --- |
| SMA (10) | 673.41 | Buy |
| EMA (10) | 673.06 | Buy |
| SMA (20) | 618.96 | Buy |
| EMA (20) | 629.43 | Buy |
| SMA (50) | 540.46 | Buy |
| EMA (50) | 554.97 | Buy |
| SMA (100) | 458.06 | Buy |
| EMA (100) | 474.41 | Buy |
| SMA (200) | 325.81 | Buy |
| EMA (200) | 375.5 | Buy |

### Oscillators — summary: **Neutral**

| Indicator | Value | Signal |
| --- | --- | --- |
| RSI (14) | 76.55 | Sell |
| MACD (12,26,9) | 52.94 | Buy |
| Stochastic (14,3,3) | 88.19 | Sell |
| ADX (14) | 36.42 | Buy |
| Williams %R (14) | -2.76 | Sell |
| ATR (14) | 33.59 | High Volatility |
| ROC (12) | 26.37 | Buy |
| Stoch RSI (14) | 62.81 | Neutral |
| UO (7,14,28) | 69.97 | Neutral |

## Filings & Documents

### Exchange Filings & Announcements

| Date | Document |
| --- | --- |
| 2026-09-04 | [Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=998874f9-cd8c-4393-a450-22743925b463.pdf) |
| 2026-09-02 | [Post-Offer Advertisement](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=D265CACB-EC25-4669-A5F5-0E3957175E9E-100805.pdf) |
| 2026-08-25 | [Announcement under Regulation 30 (LODR)-Newspaper Publication](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=87a7ffcb-0361-43f3-b8d5-dee8724426ab.pdf) |
| 2026-08-21 | [Announcement under Regulation 30 (LODR)-Newspaper Publication](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e6aba2b3-5901-4e79-b1f9-a38a77b47ff4.pdf) |
| 2026-08-20 | [Shareholder Meeting / Postal Ballot-Notice of Postal Ballot](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=3b40f653-35ba-45f3-b485-f7dd64d58ffc.pdf) |
| 2026-08-14 | [Announcement under Regulation 30 (LODR)-Newspaper Publication](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=de723762-78e9-45d6-986f-90f0e490fbee.pdf) |
| 2026-08-12 | [Board Meeting Outcome for Outcome Of Board Meeting Held On Wednesday August 12 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d65ed706-c2af-4468-be0d-ca5085217226.pdf) |
| 2026-08-12 | [Grant Of Options Under Bliss GVS Pharma Limited - Employee Stock Options Plan 2019](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=733accd5-ec86-464e-9891-a80b686bbfef.pdf) |
| 2026-08-11 | [Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=013C0BE2_77E9_4360_B6EE_6B03C1041903_132421.pdf) |
| 2026-08-11 | [Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=77553ba4-efa9-4179-92f6-ad0153d80234.pdf) |

### Results & Financial Statements

| Date | Document |
| --- | --- |
| 2026-08-12 | [Outcome Of Board Meeting Held On Wednesday August 12 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=72d9c70a-cbc7-4bb4-9266-67c88fdd1a2a.pdf) |
| 2026-05-12 | [Audited Standalone & Consolidated Financial Results For The Quarter And Year Ended March 31 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=65f7452b-8d47-4629-8ffd-847bcbec61bc.pdf) |
| 2026-02-10 | [Outcome Of Board Meeting Held On Tuesday February 10 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=26cda15c-8e7d-456e-96e9-59883a60df9a.pdf) |
| 2025-11-06 | [Unaudited Standalone And Consolidated Financial Results For The Quarter And Half Yearly Ended September 30 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d9fde745-9e3e-4712-869a-bc028b3247ac.pdf) |
| 2025-07-29 | [Outcome Of Board Meeting Held On Tuesday July 29 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a9d22cd4-35e4-434a-8657-51f2cb5e952a.pdf) |
| 2025-01-28 | [Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter And Nine Months Ended December 31 2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7d8e8259-1b09-4cad-9377-3237fcfc95df.pdf) |
| 2024-07-24 | [Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter Ended June 30, 2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=a796ae32-e72c-4a45-affa-ba13fd874545.pdf) |
| 2024-05-02 | [Audited Standalone And Consolidated Financial Results Of The Company For The Quarter And Year Ended March 31, 2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c7ec929e-baca-4fa9-887e-24a463f7d69b.pdf) |
| 2024-01-23 | [Unaudited Standalone And Consolidated Financial Results For The Quarter And Nine Months Ended December 31, 2023](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9e92191f-a411-4e93-a37b-48be6876ac0d.pdf) |
| 2023-11-01 | [Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter And Half Year Ended September 30, 2023](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b48acac1-1434-459e-9f49-dd5f6cb99b74.pdf) |

### Other Documents

| Date | Document |
| --- | --- |
| 9 Apr - Postal ballot on appointing Vijayanarayanan Mahadevan and Deepak Shah as independent directors for five years; e-voting Apr 10-May 9, 2026. | [Shareholder Meeting / Postal Ballot-Notice of Postal Ballot 9 Apr - Postal ballot on appointing Vijayanarayanan Mahadevan and Deepak Shah as independent directors for five years; e-voting Apr 10-May 9, 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/3aed1c39-e7fa-4072-a8cb-ea4bb69ef855.pdf) |
| 8h - Certificate under Regulation 74(5) of SEBI (DP) Regulations 2018 for the quarter ended March 31, 2026. | [Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 8h - Certificate under Regulation 74(5) of SEBI (DP) Regulations 2018 for the quarter ended March 31, 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/2f7eb250-6334-4e65-a303-2015a1289309.pdf) |
| 8h - Bliss GVS Pharma appoints two independent directors for five years from April 3, 2026. | [Outcome Of The Circular Resolution Passed By The Board 8h - Bliss GVS Pharma appoints two independent directors for five years from April 3, 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/0781d763-6341-41d3-bb41-b86aec56ec2b.pdf) |
| 8 Apr - ICRA assigned [ICRA]A-(Stable)/A2+ rating to Bliss GVS Pharma's Rs100 crore facilities on April 8, 2026. | [Announcement under Regulation 30 (LODR)-Credit Rating 8 Apr - ICRA assigned [ICRA]A-(Stable)/A2+ rating to Bliss GVS Pharma's Rs100 crore facilities on April 8, 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/4de531fb-f6ed-4e53-ae9c-f23868393817.pdf) |
| 6 Apr - Newspaper Advertisement published on April 04, 2026. | [Announcement under Regulation 30 (LODR)-Newspaper Publication 6 Apr - Newspaper Advertisement published on April 04, 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/440eeccc-e07d-402d-a6c3-87b7b17de9cd.pdf) |
| 5 May - Board meeting on May 12, 2026 to approve audited FY26 results and consider final dividend. | [Board Meeting Intimation for Approval Of Audited (Standalone & Consolidated) Financial Results Of The Company For The Quarter And Year Ended March 31, 2026 And Recommendation Of Final Dividend If Any, For The Year Ended March 31, 2026. 5 May - Board meeting on May 12, 2026 to approve audited FY26 results and consider final dividend.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/2f83fece-0a4f-48b8-bda2-1c9a3020f808.pdf) |
| 3 Apr - Bliss GVS Pharma appointed two independent directors from April 3, 2026, and approved postal ballot notice. | [Announcement under Regulation 30 (LODR)-Change in Directorate 3 Apr - Bliss GVS Pharma appointed two independent directors from April 3, 2026, and approved postal ballot notice.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/4e29944b-bcfd-4e93-8fb9-d5b7fc29455d.pdf) |
| 17 Feb - Interim dividend Re.0.50/share; record date Feb 18, 2026; TDS procedures; document cut-off Feb 23, 2026. | [Communication To The Shareholders Regarding Tax Deduction On Interim Dividend Declared On February 10, 2026 17 Feb - Interim dividend Re.0.50/share; record date Feb 18, 2026; TDS procedures; document cut-off Feb 23, 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/4b6e87dc-bab0-4993-b09d-1cb24db6fae0.pdf) |
| 13 Feb - Feb 13, 2026: Bliss GVS denies CNBC report suggesting acquisition/tie-up with Anupam Rasayan; no decision made. | [Rumour verification - Regulation 30(11) 13 Feb - Feb 13, 2026: Bliss GVS denies CNBC report suggesting acquisition/tie-up with Anupam Rasayan; no decision made.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/36e3f27b-b824-492b-a9e0-710cb83c3696.pdf) |
| 13 Feb - Company denies CNBC आवाज़ report about taking Anupam Rasayan; no arrangement/decision finalized as of Feb 13, 2026. | [Clarification On News Item Appearing In 'CNBC ?????' On February 13, 2026 13 Feb - Company denies CNBC आवाज़ report about taking Anupam Rasayan; no arrangement/decision finalized as of Feb 13, 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/0f3b072a-60f1-4fc9-a511-eb9f3cd33141.pdf) |

### Annual Reports

| Date | Document |
| --- | --- |
| from bse | [Annual Report 2026 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/97f1126d-cbe9-4f54-81da-c2bf20ac7100.pdf) |
| from bse | [Annual Report 2025 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/083c7bbb-21cb-4261-a80e-1f2c2edb7557.pdf) |
| from bse | [Annual Report 2024 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/6626247a-48fe-449a-b358-2fecc46a3a33.pdf) |
| from bse | [Annual Report 2023 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/e6e1ea8e-1d51-4f21-a989-9478b11ec4f6.pdf) |
| from bse | [Annual Report 2022 from bse](https://www.bseindia.com/bseplus/AnnualReport/506197/73123506197.pdf) |
| from bse | [Annual Report 2021 from bse](https://www.bseindia.com/bseplus/AnnualReport/506197/70158506197.pdf) |
| from bse | [Annual Report 2020 from bse](https://www.bseindia.com/bseplus/AnnualReport/506197/65644506197.pdf) |
| from bse | [Annual Report 2019 from bse](https://www.bseindia.com/bseplus/AnnualReport/506197/5061970319.pdf) |
| from bse | [Annual Report 2018 from bse](https://www.bseindia.com/bseplus/AnnualReport/506197/5061970318.pdf) |
| from bse | [Annual Report 2017 from bse](https://www.bseindia.com/bseplus/AnnualReport/506197/5061970317.pdf) |

### Earnings Call Documents

| Date | Document |
| --- | --- |
| Nov 2018 | [Concall - Nov 2018](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=62f1fedd-57ed-4ad9-bc6a-61f9ca2b5ead.pdf) |
| Nov 2018 | [Concall - Nov 2018](https://www.bseindia.com/xml-data/corpfiling/CorpAttachment/2018/11/62f1fedd-57ed-4ad9-bc6a-61f9ca2b5ead.pdf) |
| May 2019 | [Concall - May 2019](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=01835fde-6f36-4ab0-ad0c-5e937fabb784.pdf) |
| May 2019 | [Concall - May 2019](https://www.bseindia.com/xml-data/corpfiling/AttachHis/01835fde-6f36-4ab0-ad0c-5e937fabb784.pdf) |
| May 2018 | [Concall - May 2018](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=14b519cf-b9eb-4a57-b944-b05d0cc3815d.pdf) |
| May 2018 | [Concall - May 2018](https://www.bseindia.com/xml-data/corpfiling/CorpAttachment/2018/5/14b519cf-b9eb-4a57-b944-b05d0cc3815d.pdf) |
| Jan 2018 | [Concall - Jan 2018](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=3b9160df-881b-4653-babf-d71bdc438f0e.pdf) |
| Jan 2018 | [Concall - Jan 2018](https://www.bseindia.com/xml-data/corpfiling/CorpAttachment/2018/1/3b9160df-881b-4653-babf-d71bdc438f0e.pdf) |
| Feb 2019 | [Concall - Feb 2019](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f4267b0c-e6ab-4fab-96a7-9730873c07d6.pdf) |
| Feb 2019 | [Concall - Feb 2019](https://www.bseindia.com/xml-data/corpfiling/CorpAttachment/2019/2/f4267b0c-e6ab-4fab-96a7-9730873c07d6.pdf) |

---

Provenance differs by section. Financial statements, shareholding and filings are as reported in company disclosures to NSE/BSE/SEBI. Price, volume and 52-week levels are exchange market data. Technical indicators are computed by Tapetide from daily closing prices. The Tapetide Score is Tapetide's own analysis. Analyst ratings are third-party estimates, not company statements. All figures are for research and information only and are not investment advice. Generated 2026-09-13T20:00:07.652Z.